Percutaneous Heart Pump Devices Market
The market for Percutaneous Heart Pump Devices was estimated at $1.1 billion in 2024; it is anticipated to increase to $1.8 billion by 2030, with projections indicating growth to around $2.8 billion by 2035.
Global Percutaneous Heart Pump Devices Market Outlook
Revenue, 2024
Forecast, 2034
CAGR, 2025 - 2034
The Percutaneous Heart Pump Devices industry revenue is expected to be around $1.1 billion in 2025 and expected to showcase growth with 9.5% CAGR between 2025 and 2034. The remarkable growth pattern indicates that Percutaneous Heart Pump Devices are crucial in the medical equipment sector due to advancements in heart care and the rise in elderly population globally leading to an increased occurrence of heart ailments along with improvements in minimally invasive heart procedures driving market growth substantially research and technological progress play a key role sustaining the need for these devices, in modern healthcare setups. Emphasizing safety and comfort has become a key priority with Percutaneous Heart Pump Devices showcasing the value of advanced medical technology in enhancing health results and instilling trust in patients well being. Given these considerations it is apparent that these devices will play a role, in shaping the future of healthcare practices.
Perforated Heart Pump Devices are tools created to enhance blood flow in people with heart failure by lessening the strain put upon the heart muscle. They are known for being invasive and user friendly devices that perform well and can be used in various important heart related procedures due, to their biocompatible design.
Market Key Insights
The Percutaneous Heart Pump Devices market is projected to grow from $1.1 billion in 2024 to $2.6 billion in 2034. This represents a CAGR of 9.5%, reflecting rising demand across Treatment of Cardiovascular Diseases, Pre & Post-Operative Support, and Interventional Cardiology.
Abbott Laboratories, Medtronic Inc., and Teleflex Incorporated are among the leading players in this market, shaping its competitive landscape.
U.S. and Germany are the top markets within the Percutaneous Heart Pump Devices market and are expected to observe the growth CAGR of 6.9% to 10.0% between 2024 and 2030.
Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 9.1% to 11.9%.
Transition like Technological Advancements is expected to add $196 million to the Percutaneous Heart Pump Devices market growth by 2030.
The Percutaneous Heart Pump Devices market is set to add $1.6 billion between 2024 and 2034, with manufacturer targeting Acute Myocardial Infarction & Cardiogenic Shock Application projected to gain a larger market share.
With Increasing prevalence of cardiovascular diseases, and technological advancements in Percutaneous Heart Pump Devices, Percutaneous Heart Pump Devices market to expand 148% between 2024 and 2034.
Opportunities in the Percutaneous Heart Pump Devices
Growth Opportunities in North America and Asia Pacific
Market Dynamics and Supply Chain
Driver: Increasing prevalence of cardiovascular diseases, and Increasing healthcare expenditures and favorable insurance policies
Restraint: High Cost and Limited Reimbursement
Opportunity: Strategic Collaborations and Partnerships and Expansion into Underserved Markets
Challenge: Lack of Training and Complexities in Operation
Supply Chain Landscape
Raw Material Procurement
Device Production
Marketing & Sales
End User
Raw Material Procurement
Device Production
Marketing & Sales
End User
Use Cases of Percutaneous Heart Pump Devices in Treatment of Cardiovascular Diseases & Pre & Post-Operative Support
Recent Developments
The medical devices industry has been making significant strides in product innovation, with Percutaneous Heart Pump Devices at the forefront. This industry has been experiencing dynamic shifts characterized by new technologies, advanced applications, and evolving market trends. Percutaneous Heart Pumps, external cardiac support solutions, are instrumental in treating heart complications.